Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
161.31B
Market cap161.31B
Price-Earnings ratio
10.48
Price-Earnings ratio10.48
Dividend yield
3.37%
Dividend yield3.37%
Average volume
18.40M
Average volume18.40M
High today
$37.33
High today$37.33
Low today
$35.86
Low today$35.86
Open price
$36.47
Open price$36.47
Volume
26.37M
Volume26.37M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.85
52 Week low$35.85

NVO News

Simply Wall St 6h
A Look At Hims & Hers Health Valuation After Novo Nordisk Renews Weight Loss Drug Partnership

The sharp recent move in Hims & Hers Health (HIMS) comes after Novo Nordisk agreed to resume selling its weight loss drugs on the platform, ending a public lega...

A Look At Hims & Hers Health Valuation After Novo Nordisk Renews Weight Loss Drug Partnership
Simply Wall St 12h
Novo Nordisk’s GLP-1 Leadership Tested By FDA Warnings And Rising Rivals

Novo Nordisk (NYSE:NVO) has received two recent FDA warnings related to its GLP-1 franchise. The company is experiencing rising GLP-1 competition from Eli Lill...

Novo Nordisk’s GLP-1 Leadership Tested By FDA Warnings And Rising Rivals
Nasdaq 1d
This Hims & Hers Move Could Destroy Competitors

Key Points The recent deal between Novo Nordisk and Hims & Hers is already resulting in new product announcements for Hims & Hers. The fastest GLP-1 launch in...

This Hims & Hers Move Could Destroy Competitors

Analyst ratings

59%

of 34 ratings
Buy
32.4%
Hold
58.8%
Sell
8.8%

More NVO News

Nasdaq 2d
Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?

Key Points Novo Nordisk unveiled a troubling guidance for 2026, which tanked the stock. It recently reached a deal with telehealth company Hims & Hers Health...

Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?
TipRanks 2d
$14 Generic Wegovy Coming to India as Novo Nordisk Patent Expires

Indian drugmakers are preparing to launch generic versions of Novo Nordisk’s (NVO) semaglutide treatments once the patent expires on Friday. In fact, about 42 m...

Nasdaq 2d
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients

Novo Nordisk NVO announced that the FDA has approved Wegovy HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight redu...

FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
Simply Wall St 2d
Has Novo Nordisk Fallen Too Far After Its 52% One Year Share Price Decline

If you are wondering whether Novo Nordisk's current share price still reflects its long term potential, you are not alone. This article focuses squarely on what...

Has Novo Nordisk Fallen Too Far After Its 52% One Year Share Price Decline
Benzinga 3d
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy

• Novo Nordisk shares are experiencing downward pressure. What’s pulling NVO shares down? The approval comes via the Commissioner's National Priority Voucher (...

Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
The Wall Street Journal 3d
Novo Nordisk’s Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval

Novo Nordisk’s Wegovy higher dosage medication contains 7.2 mg of semaglutide, injected once weekly, it said. Tom Little/Reuters Novo Nordisk’s NOVO.B -1.49 %d...

Novo Nordisk’s Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval
CNBC 3d
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. The Food and Drug Adminis...

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.